Literature DB >> 26926229

Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS.

P B Dahi1,2, E Morawa1,2, M-A Perales1,2, E C Zabor3, S M Devlin3, M Maloy1, H Castro-Malaspina1,2, R J O'Reilly2,4, E B Papadopoulos1,2, A A Jakubowski1,2, S A Giralt1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26926229      PMCID： PMC5358510          DOI： 10.1038/bmt.2016.23

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

Authors:  John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

3.  Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.

Authors:  Erica D Warlick; Todd DeFor; Bruce R Blazar; Linda Burns; Michael R Verneris; Celalettin Ustun; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-10       Impact factor: 5.742

4.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.

Authors:  E B Papadopoulos; M H Carabasi; H Castro-Malaspina; B H Childs; S Mackinnon; F Boulad; A P Gillio; N A Kernan; T N Small; P Szabolcs; J Taylor; J Yahalom; N H Collins; S A Bleau; P M Black; G Heller; R J O'Reilly; J W Young
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

5.  Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.

Authors:  Steven M Devine; Shelly Carter; Robert J Soiffer; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Edward A Stadtmauer; Edwin P Alyea; Carolyn A Keever-Taylor; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-12       Impact factor: 5.742

6.  Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.

Authors:  Nelli Bejanyan; Daniel J Weisdorf; Brent R Logan; Hai-Lin Wang; Steven M Devine; Marcos de Lima; Donald W Bunjes; Mei-Jie Zhang
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-15       Impact factor: 5.742

Review 7.  Relapse after allogeneic hematopoietic cell therapy.

Authors:  Marcel R M van den Brink; David L Porter; Sergio Giralt; Sydney X Lu; Robert R Jenq; Alan Hanash; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742

8.  Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Authors:  Pramila Krishnamurthy; Victoria T Potter; Linda D Barber; Austin G Kulasekararaj; Zi Yi Lim; Rachel M Pearce; Hugues de Lavallade; Michelle Kenyon; Robin M Ireland; Judith C W Marsh; Stephen Devereux; Antonio Pagliuca; Ghulam J Mufti
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-21       Impact factor: 5.742

9.  Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia.

Authors:  Raynier Devillier; Roberto Crocchiolo; Anne Etienne; Thomas Prebet; Aude Charbonnier; Sabine Fürst; Jean El-Cheikh; Evelyne D'Incan; Jérôme Rey; Catherine Faucher; Didier Blaise; Norbert Vey
Journal:  Leuk Lymphoma       Date:  2012-11-19

10.  Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.

Authors:  D A Pollyea; A S Artz; W Stock; C Daugherty; L Godley; O M Odenike; E Rich; S M Smith; T Zimmerman; Y Zhang; D Huo; R Larson; K van Besien
Journal:  Bone Marrow Transplant       Date:  2007-09-10       Impact factor: 5.483
View more
  4 in total

1.  Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.

Authors:  Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-23       Impact factor: 5.742

2.  Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation.

Authors:  Yao-Ting Huang; Seong Jin Kim; Yeon Joo Lee; Daniel Burack; Paige Nichols; Molly Maloy; Miguel-Angel Perales; Sergio A Giralt; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-28       Impact factor: 5.742

3.  Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.

Authors:  Corrado Zuanelli Brambilla; Stephanie M Lobaugh; Josel D Ruiz; Parastoo B Dahi; Aaron D Goldberg; James W Young; Boglarka Gyurkocza; Brian C Shaffer; Doris M Ponce; Roni Tamari; Miriam Sanchez Escamilla; Nerea Castillo Flores; Ioannis Politikos; Michael Scordo; Gunjan L Shah; Christina Cho; Richard J Lin; Molly A Maloy; Sean M Devlin; Ann A Jakubowski; Ellin Berman; Eytan M Stein; Esperanza B Papadopoulos; Miguel-Angel Perales; Martin S Tallman; Sergio A Giralt; Melody Smith
Journal:  Transplant Cell Ther       Date:  2021-05-24

4.  Refractory autoimmune haemolytic anaemia following allogenic haematopoietic stem cell transplantation: successful treatment of rituximab.

Authors:  Xiaofan Li; Jiafu Huang; Zhijuan Zhu; Nainong Li
Journal:  J Int Med Res       Date:  2019-07-07       Impact factor: 1.671
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.